Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM | Learn More
Logo yposkesi
waves image

A large-scale lentivirus manufacturing platform to accelerate time to clinic: video & poster

Watch the video to learn more about:

  • LentiSure™, a proven large-scale lentivirus production platform to accelerate time to clinic of lentivirus-based cell and gene therapies
  • Achieving high titers, transduction efficiency, dependability, and scalable production processes with improved purification methods
  • Optimized analytical methods to allow faster development and improved patient results

Fill out the form to watch LentiSure vidéo (10min)

  • This field is for validation purposes and should be left unchanged.

Do you prefer to read a poster?

Download Fast Fact LentiSure poster

  • This field is for validation purposes and should be left unchanged.

About the speaker: Brian Mullan, PhD, Chief Technical Officer at Yposkesi

Brian joined Yposkesi as Chief Technical Officer in 2020. With over 20 years of experience working internationally (Europe, USA) with large multinational companies, Brian has held leadership roles in late-phase process development, product launch, and commercial supply for large pharmaceutical companies making therapeutic monoclonal antibodies (MAbs). He spent nine years at Novartis, where he held posts as head of manufacturing science and technology and as a global technical project leader. Between 2008 and 2012, he was process tech transfer lead at Eli Lilly. Prior to that, he worked at Janssen (Centocor) Biologics and Sanofi-Aventis (in the area of C&GT R&D). He holds a PhD in Viral Genetics from University College Cork, Ireland, and an MBA from the Open University Business School, UK.

Created by Yerokhoff Kostyiantine